SOLACE 2 : A Phase II randomised trial comparing immune priming by low dose oral cyclophosphamide plus olaparib versus priming by olaparib alone, prior to combination therapy with olaparib plus durvalumab, versus single agent olaparib alone, in asymptomatic platinum-sensitive recurrent ovarian, fallopian tube or primary peritoneal cancers with homologous recombination repair defects

Female<br/>OnlyGender Female
Only

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

TwoPhase Two

18+Age Over 18

Female Reproductive<br/>System CancersCancer LocationFemale Reproductive
System Cancers

Systemic therapy | Female reproductive organsEpithelial,Fallopian tube,Ovary,Peritoneal

Trial Overview Read MoreRead more

This Phase II trial is comparing the effectiveness of a chemotherapy drug (Olaparib) alone and as part of a combination therapy in patients with recurrent ovarian, fallopian tube or primary peritoneal cancers that have homologous recombination repair defects.
 

This trial is treating patients with Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer.

This is a systemic therapy trial.

You may be able to join this trial if:

  • You have had treatment, but your cancer has come back.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.
  • You have previously been treated (or are currently being treated) on a clinical trial.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Phase II randomised trial comparing immune priming by low dose oral cyclophosphamide plus olaparib versus priming by olaparib alone, prior to combination therapy with olaparib plus durvalumab, versus single agent olaparib alone, in asymptomatic platinum-sensitive recurrent ovarian, fallopian tube or primary peritoneal cancers with homologous recombination repair defects

Other Non-Commercial Sponsor

University of Sydney

Summary

Participants will be randomised to receive treatment according to one of the following three groups: (1) Olaparib and cyclophosphamide (50mg daily) followed by olaparib and durvalumab (1500mg every 4 weeks for 12 cycles), or (2) Olaparib followed by olaparib and durvalumab (as above), or (3) Olaparib alone. In each group, 300mg Olaparib will be administered orally, twice daily until progression occurs.

Recruiting Hospitals Read MoreRead more

Frankston Hospital
Frankston
Ms Judy Reilly
judithreilly@phcn.vic.gov.au
03 9784 8520

PCCTU (Parkville Cancer Clinical Trials Unit) *
Parkville
Ms Marian Lieschke
marian.lieschke@petermac.org
03 8559 7140

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next